| 6.81 -0.15 (-2.16%) | 09-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.17 | 1-year : | 16.11 |
| Resists | First : | 10.42 | Second : | 13.8 |
| Pivot price | 6.38  |
|||
| Supports | First : | 4.96 | Second : | 4.13 |
| MAs | MA(5) : | 5.3 |
MA(20) : | 6.2 |
| MA(100) : | 6.54 |
MA(250) : | 6.04 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 1.7  |
D(3) : | 2.1 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 15.81 | Low : | 2.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRTG ] has closed above bottom band by 28.6%. Bollinger Bands are 97.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.31 - 5.34 | 5.34 - 5.36 |
| Low: | 5.02 - 5.04 | 5.04 - 5.06 |
| Close: | 5.09 - 5.12 | 5.12 - 5.16 |
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Wed, 03 Sep 2025
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem - GlobeNewswire
Wed, 25 Jun 2025
Portage Biotech regains Nasdaq compliance, continues listing By Investing.com - Investing.com Canada
Wed, 25 Jun 2025
Portage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market - Nasdaq
Wed, 25 Jun 2025
Portage Biotech Clears All Nasdaq Listing Requirements, Confirms Market Position - Stock Titan
Mon, 09 Jun 2025
Portage Biotech acquires stake in Compedica for $5 million - Investing.com
Mon, 14 Apr 2025
PRTG Stock Surges 68% Amid High Volume; Analysts Warn of Overvaluation Risks Ahead - StockInvest.us
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 60.5 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -5.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -92.7 % |
| Return on Equity (ttm) | -541.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.9 |
| PEG Ratio | 0 |
| Price to Book value | -73.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|